Home
Life Sciences
Pharmaceutical
Drug and Medication
Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Drug & Medication

Summary

Table of Contents

Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Publication date: August 2010

Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets Summary GBI Research’s report, “Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global women’...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets

Summary

GBI Research’s report, “Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global women’s health market. The report analyzes the markets for women’s health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The Scope of this report includes:
- Annualized market data for the women’s health market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including osteoporosis, hormone therapy for menopause, endometriosis, women’s infertility and polycistic ovarian syndrome.
- Analysis of the women’s health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the women’s health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Merck, Pfizer, Johnson & Johnson, Teva Pharmaceuticals and Bayer-Schering Pharma.
- Key M&A activities, licensing agreements, that have taken place in 2009 in the global blood disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Global Drug And Medication Industry

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7
2 Global WH Disorder Therapeutics Market:Introduction 10
2.1 GBI Research Report Guidance 10
3 Global WH Disorder Therapeutics Market: Market Characterization 11
3.1 Introduction 11
3.2 Revenue Forecasts for the Global WH Disorder Therapeutics Market 12
3.2.1 Sales Value 12
3.2.2 Annual Cost of Therapy 13
3.2.3 Treatment Usage Patterns 14
3.2.4 Generics’ Share in the Global WH Disorder Therapeutics Market 20
4 Global WH Disorder Therapeutics Market: Therapeutic Landscape 21
4.1 Global Menopause Therapeutics Market 21
4.1.1 Introduction 21
4.1.2 Sales Value 21
4.1.3 Annual Cost of Therapy 23
4.1.4 Treatment Usage Patterns 24
4.1.5 Drivers and Barriers for the Menopause Therapeutics Market 30
4.1.6 Market share by Geography 31
4.1.7 Product Analysis 33
4.2 Global Endometriosis Therapeutics Market 38
4.2.1 Introduction 38
4.2.2 Sales Value 39
4.2.3 Annual Cost of Therapy 40
4.2.4 Treatment Usage Patterns 41
4.2.5 Drivers and Barriers for the Endometriosis Therapeutics Market 46
4.2.6 Market share by Geography 47
4.2.7 Product Analysis 48
4.3 Global Postmenopausal Osteoporosis (PMO) Market 51
4.3.1 Introduction 51
4.3.2 Sales Value 52
4.3.3 Annual Cost of Therapy 53
4.3.4 Treatment Usage Patterns 54
4.3.5 Drivers and Barriers for the Menopause Therapeutics Market 60
4.3.6 Market Share by Geography 61
4.3.7 Product Analysis 63
5 Global WH Disorder Therapeutics Market: Geographical Landscape 68
5.1 Geographical Break-up 68
5.2 The US 71
5.2.1 Sales Value 71
5.2.2 Annual Cost of Therapy 72
5.2.3 Treatment Usage Patterns 73
5.3 Top Five Markets in Europe 78
5.3.1 Sales Value 78
5.3.2 Annual Cost of Therapy 79
5.3.3 Treatment Usage Patterns 80
5.4 Japan 85
5.4.1 Sales Value 85
5.4.2 Annual Cost of Therapy 86
5.4.3 Treatment Usage Patterns 87
6 Global WH Disorder Therapeutics Market: Pipeline Analysis 92
6.1 Introduction 92
6.1.1 Research and Development Pipeline – Menopause 94
6.1.2 Research and Development Pipeline – Endometriosis 96
6.1.3 Research and Development Pipeline - Postmenopausal Osteoporosis 98
6.2 Profiles of Key Late-Stage Drugs in the WH disorder Therapeutics Market 101
6.2.1 Aprela (Bazedoxifene/Conjugated Estrogen) 101
6.2.2 Pristiq (Desvenlaxafine, DVS-233) 102
6.2.3 Visanne 103
6.2.4 Elagolix (NBI-56418) 103
6.2.5 Odanacatib (MK-0822) 104
6.2.6 Viviant (Bazedoxifene) 105
7 Global WH Disorder Therapeutics Market: Competitive Landscape 106
7.1 Market Share Analysis: Women’s Health 106
7.2 Competitive Profiling 108
7.2.1 Pfizer Inc 108
7.3 Eli Lilly and Company 109
7.4 Merck & Co. 110
7.5 Procter & Gamble Company 112
7.6 Hoffmann-La Roche Ltd. 114
8 Global WH Disorder Therapeutics Market: Strategic Consolidations 117
8.1 Mergers and Acquisitions 117
8.1.1 Overview 117
8.1.2 Ferring Pharmaceuticals Acquires Global Rights to LYSTEDA from Xanodyne Pharmaceuticals in May 2010 121
8.1.3 BioSante Acquires Elestrin Royalty from Azur Pharma in March 2010 121
8.1.4 Teva-KOWA Pharma Acquires Majority Stake in Taisho Pharmaceutical in February 2010 121
8.1.5 Sciele Pharma Acquires Addrenex Pharmaceuticals in November 2009 121
8.1.6 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 121
8.1.7 BioSante Pharmaceuticals Merges with Cell Genesys in October 2009 122
8.1.8 Hisamitsu Pharmaceutical Completes Acquisition Of Noven Pharmaceuticals in August 2009 122
8.1.9 Pfizer Acquires Wyeth in January 2009 122
8.1.10 Par Pharmaceuticals Acquires Assets Of Calcitonin & A Manufacturing Facility From MDRNA in April 2009 122
8.2 R&D Licensing Agreements 123
8.2.1 Deals by Indication 123
8.2.2 Deals by Phase 124
8.2.3 Deals by Geography 125
9 Global WH Disorder Therapeutics Market: Appendix 126
9.1 Market Definitions 126
9.2 Abbreviations 126
9.3 Coverage 128
9.3.1 Secondary Research 128
9.3.2 Primary Research 128
9.3.3 Forecasts 129
9.3.4 Expert Panel Validation 131
9.4 Contact Us 131
9.5 Disclaimer 131
9.6 Sources 132

1.1 List of Tables
Table 1: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2001–2009 12
Table 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2009–2016 13
Table 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2009 13
Table 4: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2009–2016 14
Table 5: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2001–2009 15
Table 6: WH Disorder Therapeutics Market, Global, Treatment Usage Patterns (in millions), 2009–2016 15
Table 7: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2001–2009 22
Table 8: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2009–2016 22
Table 9: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2001–2009 23
Table 10: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2009–2016 23
Table 11: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2001–2009 25
Table 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (in millions), 2009–2016 25
Table 13: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2001–2009 39
Table 14: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2009–2016 39
Table 15: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2001–2009 40
Table 16: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2009–2016 40
Table 17: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2001–2009 41
Table 18: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (in millions), 2009–2016 42
Table 19: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2001–2009 52
Table 20: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2009–2016 52
Table 21: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2001–2009 53
Table 22: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2009–2016 54
Table 23: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2009 55
Table 24: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2009–2016 55
Table 25: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2001–2009 69
Table 26: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2009–2016 69
Table 27: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 2001–2009 71
Table 28: WH Disorder Therapeutics Market, The US, Sales Value ($bn), 2009–2016 71
Table 29: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2009 72
Table 30: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2009–2016 72
Table 31: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2009 73
Table 32: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2009–2016 74
Table 33: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2001–2009 78
Table 34: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2009–2016 78
Table 35: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2001–2009 79
Table 36: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2009–2016 79
Table 37: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2001–2009 80
Table 38: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Pattern (in millions), 2009–2016 81
Table 39: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 2001–2009 85
Table 40: WH Disorder Therapeutics Market, Japan, Sales Value ($bn), 2009–2016 85
Table 41: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2009 86
Table 42: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2009–2016 86
Table 43: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2009 87
Table 44: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2009–2016 88
Table 45: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase III Pipeline, August 2010 95
Table 46: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase II Pipeline, August 2010 95
Table 47: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Phase I Pipeline, August 2010 95
Table 48: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market, Preclinical Pipeline, August 2010 96
Table 49: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase III and Regulatory Filing, August 2010 97
Table 50: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase II Pipeline, August 2010 97
Table 51: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Phase I Pipeline, August 2010 97
Table 52: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Endometriosis Market, Preclinical Pipeline, August 2010 97
Table 53: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase III and Regulatory Filing, August 2010 99
Table 54: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase II Pipeline, August 2010 99
Table 55: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Phase I Pipeline, August 2010 99
Table 56: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market, Preclinical Pipeline, August 2010 100
Table 57: WH Disorder Therapeutics Market, Global, Major M&A Deals, 2009–2010 120

1.2 List of Figures
Figure 1: Women’s Health Market, Global, Drivers and Restraints, 2009 11
Figure 2: WH Disorder Therapeutics Market, Global, Sales Value ($bn), 2001–2016 12
Figure 3: WH Disorder Therapeutics Market, Global, Annual Cost of Therapy ($), 2001–2016 13
Figure 4: WH Disorder Therapeutics Market, Global, Therapeutic Usage Patterns, 2001–2016 14
Figure 5: WH Disorder Therapeutics Market, Global, Diseased Population (in millions), 2001–2016 16
Figure 6: WH Disorder Therapeutics Market, Global, Treatment Seeking Population (in millions), 2001–2016 17
Figure 7: WH Disorder Therapeutics Market, Global, Diagnosed Population (in millions), 2001–2016 18
Figure 8: WH Disorder Therapeutics Market, Global, Prescription Population (in millions), 2001–2016 19
Figure 9: WH Disorder Therapeutics Market, Global, Branded v/s Generic Drugs, $bn, 2001–2016 20
Figure 10: WH Disorder Therapeutics Market, Global, Menopause Sales Value ($bn), 2001–2016 22
Figure 11: WH Disorder Therapeutics Market, Global, Menopause Annual Cost of Therapy ($), 2001–2016 23
Figure 12: WH Disorder Therapeutics Market, Global, Menopause Treatment Usage Patterns (million), 2001–2016 24
Figure 13: WH Disorder Therapeutics Market, Global, Menopause Diseased Population (in millions), 2001–2016 26
Figure 14: WH Disorder Therapeutics Market, Global, Menopause Treatment Seeking Population (in millions), 2001–2016 27
Figure 15: WH Disorder Therapeutics Market, Global, Menopause Diagnosis Population (in millions), 2001–2016 28
Figure 16: WH Disorder Therapeutics Market, Global, Menopause Prescription Population (in millions), 2001–2016 29
Figure 17: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2009 and 2016 31
Figure 18: WH Disorder Therapeutics Market, Global, Menopause, Market Segmentation by Geography, 2001 - 2016 32
Figure 19: WH Disorder Therapeutics Market, Global, Endometriosis Sales Value ($bn), 2001–2016 39
Figure 20: WH Disorder Therapeutics Market, Global, Endometriosis Annual Cost of Therapy ($), 2001–2016 40
Figure 21: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Usage Patterns (million), 2001–2016 41
Figure 22: WH Disorder Therapeutics Market, Global, Endometriosis Diseased Population (in millions), 2001–2016 42
Figure 23: WH Disorder Therapeutics Market, Global, Endometriosis Treatment Seeking Population (in millions), 2001–2016 43
Figure 24: WH Disorder Therapeutics Market, Global, Endometriosis Diagnosis Population (in millions), 2001–2016 44
Figure 25: WH Disorder Therapeutics Market, Global, Endometriosis Prescription Population (in millions), 2001–2016 45
Figure 26: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2009 and 2016 47
Figure 27: WH Disorder Therapeutics Market, Global, Endometriosis, Market Segmentation by Geography, 2001 - 2016 48
Figure 28: WH Disorder Therapeutics Market, Global, PMO Sales Value ($bn), 2001–2016 52
Figure 29: WH Disorder Therapeutics Market, Global, PMO Annual Cost of Therapy ($), 2001–2016 53
Figure 30: WH Disorder Therapeutics Market, Global, PMO Treatment Usage Patterns (in millions), 2001–2016 54
Figure 31: WH Disorder Therapeutics Market, Global, PMO Diseased Population (in millions), 2001–2016 56
Figure 32: WH Disorder Therapeutics Market, Global, PMO Treatment Seeking Population (in millions), 2001–2016 57
Figure 33: WH Disorder Therapeutics Market, Global, PMO Diagnosis Population (in millions), 2001–2016 58
Figure 34: WH Disorder Therapeutics Market, Global, PMO Prescription Population (in millions), 2001–2016 59
Figure 35: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009 and 2016 61
Figure 36: WH Disorder Therapeutics Market, Global, PMO, Market Segmentation by Geography, 2009–2016 62
Figure 37: WH Disorder Therapeutics Market, Global, Market Share by Geography, 2009 and 2016 68
Figure 38: WH Disorder Therapeutics Market, Global, Sales Value by Geography ($bn), 2001–2016 69
Figure 39: WH Disorder Therapeutics Market, Global, Geography Benchmarking, 2009 and 2016 70
Figure 40: WH Disorder Therapeutics Market, US, Sales Value ($bn), 2001–2016 71
Figure 41: WH Disorder Therapeutics Market, The US, Annual Cost of Therapy ($), 2001–2016 72
Figure 42: WH Disorder Therapeutics Market, The US, Treatment Usage Patterns (in millions), 2001–2016 73
Figure 43: WH Disorder Therapeutics Market, The US, Diseased Population (in millions), 2001–2016 74
Figure 44: WH Disorder Therapeutics Market, The US, Treatment Seeking Population (in millions), 2001–2016 75
Figure 45: WH Disorder Therapeutics Market, The US, Diagnosis Population (in millions), 2001–2016 76
Figure 46: WH Disorder Therapeutics Market, The US, Prescription Population (in millions), 2001–2016 77
Figure 47: WH Disorder Therapeutics Market, Top Five Markets in Europe, Sales Value ($bn), 2001–2016 78
Figure 48: WH Disorder Therapeutics Market, Top Five Markets in Europe, Annual Cost of Therapy ($), 2001–2016 79
Figure 49: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Usage Patterns (in millions), 2001–2016 80
Figure 50: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diseased Population (in millions), 2001–2016 81
Figure 51: WH Disorder Therapeutics Market, Top Five Markets in Europe, Treatment Seeking Population (in millions), 2001–2016 82
Figure 52: WH Disorder Therapeutics Market, Top Five Markets in Europe, Diagnosis Population (in millions), 2001–2016 83
Figure 53: WH Disorder Therapeutics Market, Top Five Markets in Europe, Prescription Population (in millions), 2001–2016 84
Figure 54: WH Disorder Therapeutics Market, Japan, Sales Value ($m), 2001–2016 85
Figure 55: WH Disorder Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001–2016 86
Figure 56: WH Disorder Therapeutics Market, Japan, Treatment Usage Pattern (in millions), 2001–2016 87
Figure 57: WH Disorder Therapeutics Market, Japan, Diseased Population (in millions), 2001–2016 88
Figure 58: WH Disorder Therapeutics Market, Japan, Treatment Seeking Population (in millions), 2001–2016 89
Figure 59: WH Disorder Therapeutics Market, Japan, Diagnosed Population (in millions), 2001–2016 90
Figure 60: WH Disorder Therapeutics Market, Japan, Prescription Population (in millions), 2001–2016 91
Figure 61: WH Disorder Therapeutics Market, Global, R&D Pipeline by Indication (%), August 2010 92
Figure 62: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase (%), August 2010 93
Figure 63: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Menopause Market (%), August 2010 94
Figure 64: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in the Endometriosis Therapeutics Market (%), August 2010 96
Figure 65: WH Disorder Therapeutics Market, Global, R&D Pipeline by Phase in Postmenopausal Osteoporosis Market (%), August 2010 98
Figure 66: WH Disorder Therapeutics Market, Global, Market Share of Top Manufacturers (%), 2009 106
Figure 67: WH Disorder Therapeutics Market, Global, Revenue of Top Five Players ($m), 2009 107
Figure 68: WH Disorder Therapeutics Market, Global, Average value, Revenue of Top Five Players ($m), 2009 107
Figure 69: WH Disorder Therapeutics Market, SWOT Analysis, Pfizer, 2009 109
Figure 70: WH Disorder Therapeutics Market, SWOT Analysis, Eli Lilly, 2009 110
Figure 71: WH Disorder Therapeutics Market, SWOT Analysis, Merck, 2009 111
Figure 72: WH Disorder Therapeutics Market, SWOT Analysis, Procter & Gamble, 2009 113
Figure 73: WH Disorder Therapeutics Market, SWOT Analysis, Hoffman-La Roche, 2009 116
Figure 74: WH Disorder Therapeutics Market, Global, M&A Deals by Indication (%), 2004-2010 117
Figure 75: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009 118
Figure 76: WH Disorder Therapeutics Market, Global, M&A Deals by Deal Value (%), 2009 119
Figure 77: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Indication (%), 2004–2010 123
Figure 78: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Phase (%), 2004–2010 124
Figure 79: WH Disorder Therapeutics Market, Global, Major Licensing Agreements By Geography (%), 2009–2010 125
Figure 80: GBI Research Market Forecasting Model, 2010 130

Companies mentioned
Eli Lilly and Company
Merck & Co.
Procter & Gamble Company
Hoffmann-La Roche Ltd.
Pfizer Inc

Talk to Alexandra

(866) 682 9815

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Drug And Medication Industry : Latest Reports

Vaccines - Global Markets Package

$ 24 060
Industry report
May 2013
by Global Research & Data Services

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market ...

Global Markets for Orphan Drugs

$ 5 450
Industry report
June 2013
by BCC Research

INTRODUCTION STUDY OBJECTIVES The orphan drug market is one of the fastest-growing segments in the pharmaceutical and biotechnology industry. BCC's goal in conducting this study is to provide an overview ...

Global Markets for Orphan Drugs - Focus on Biologics

$ 4 400
Industry report
June 2013
by BCC Research

Global Markets For Orphan Drugs - Focus On ...

June 2013 $ 4 400

Infertility Drugs And Devices Market - Gl ...

November 2013 $ 4 395

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Angiogenesis A ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

More Reports:

Drug and Medication in China (139)

Drug and Medication in France (48)

Drug and Medication in Germany (48)

Drug and Medication in Italy (46)

Drug and Medication in Japan (63)

Drug and Medication in Spain (43)

Drug and Me... in the United Kingdom (49)

Drug and Me... in the United States (153)

Company Reports

GlaxoSmithKline P.L.C.

Novartis Inc.

Johnson And Johnson

Pfizer Inc.

GlaxoSmithKline PLC

AstraZeneca PLC

Eli Lilly And Co.

Lilly And Co.

Amgen Inc.

Sanofi-Aventis Senegal

Global Drug And Medication Industry : Latest Downloads

Drug and Medication : Innovation and Technology Trends

Industry report
May 2013
62 pages
by Corporation

... For the patients taking placebo26. 5.2 Products and incremental innovations our focus is on four active ingredients in selective serotonin reuptake inhibitor (ssri) anti-depressant drugs, denoted in atc code as n06 ...

World Drug Industry Brief

Industry report
May 2013
7 pages

... To help to achieve this goal, through services including the supply of aff ordable, quality-assured drugs to countries in need. We assess the scale of gdf drug supplies worldwide and fi nd that the gdf ...

Drug and Medication Sector Analysis

Industry report
May 2013
62 pages

More Reports:

Drug and Medication in Australia (23)

Drug and Medication in Canada (47)

Drug and Medication in China (34)

Drug and Medication in India (104)

Company Reports

Binger

Country Reports

World

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.